Goldman Sachs’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-458,096
| Closed | -$15.5M | – | 6761 |
|
|
2021
Q2 | $15.5M | Sell |
458,096
-228,512
| -33% | -$5.82M | ﹤0.01% | 2282 |
|
|
2021
Q1 | $16.1M | Sell |
686,608
-25,057
| -4% | -$759K | ﹤0.01% | 2125 |
|
|
2020
Q4 | $20.5M | Buy |
711,665
+341,483
| +92% | +$8.6M | 0.01% | 1841 |
|
|
2020
Q3 | $7.5M | Buy |
370,182
+42,890
| +13% | +$1.05M | ﹤0.01% | 2572 |
|
|
2020
Q2 | $9.84M | Buy |
327,292
+235,860
| +258% | +$8.5M | ﹤0.01% | 2286 |
|
|
2020
Q1 | $2.87M | Buy |
91,432
+78,094
| +586% | +$2.72M | ﹤0.01% | 3058 |
|
|
2019
Q4 | $628K | Sell |
13,338
-19,309
| -59% | -$557K | ﹤0.01% | 4373 |
|
|
2019
Q3 | $211K | Buy |
+32,647
| New | +$273K | ﹤0.01% | 4811 |
|
|
2019
Q2 | – | Sell |
-10,779
| Closed | -$146K | – | 5443 |
|
|
2019
Q1 | $146K | Buy |
+10,779
| New | +$96.6K | ﹤0.01% | 4866 |
|
|
2018
Q4 | – | Sell |
-15,301
| Closed | -$103K | – | 5846 |
|
|
2018
Q3 | $103K | Buy |
+15,301
| New | +$146K | ﹤0.01% | 5128 |
|
Goldman Sachs's CNST Position: Q3 2021 in Review
Goldman Sachs sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 458,096 shares — an estimated $15.5M sold.
Goldman Sachs first reported a position in CNST in Q3 2018 and held it in 10 quarters. The position peaked at $20.5M in Q4 2020. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.
- Goldman Sachs reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
- Goldman Sachs sold 458,096 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $15.5M.
- Goldman Sachs first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 10 quarters.
- Goldman Sachs's Constellation Pharmaceuticals, Inc. position peaked at $20.5M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.
Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.